Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The Effect of Tranexamic Acid (TXA) on Visualization During Shoulder Arthroscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04610164
Recruitment Status : Enrolling by invitation
First Posted : October 30, 2020
Last Update Posted : October 30, 2020
Information provided by (Responsible Party):
Rothman Institute Orthopaedics

Brief Summary:
Tranexamic acid has seen an increase in use over the past decade in hip and knee arthroplasty as well as spine surgery with more recent use seen in total shoulder arthroplasty (TSA). The mechanism of action of TXA is as a lysine analogue that competitively inhibits the conversion of plasminogen to plasmin thus resulting in its antifibrinolytic activity. Investigators have showed that compared with placebo TXA had a statistically significant effect on blood and postoperative hemoglobin levels in TSA. To date there are no studies investigating the effect of TXA in arthroscopy of any kind or studies examining the ability of TXA to aid in surgeon visualization in arthroscopic procedures. The investigators of this study will use change in pump pressure as a surrogate objective measure for surgeon visualization. The hypothesis is that participants who receive TXA will have a lower change in pump pressure compared to participants who do not receive TXA.

Condition or disease Intervention/treatment Phase
Shoulder Arthroscopy Operative Bleeding Postoperative Pain Drug: Tranexamic acid Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Tranexamic Acid on Visualization During Shoulder Arthroscopy
Actual Study Start Date : June 19, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group 1: TXA group
Patient will receive 1 gram intravenous TXA prior to surgery
Drug: Tranexamic acid
Prior to surgery, the patient will receive 1 gram of IV TXA

No Intervention: Group 2: Control Group
Patient will not receive TXA prior to surgery

Primary Outcome Measures :
  1. Changes in operative factors [ Time Frame: 2 hours ]
    change in pump pressure (ΔP) during shoulder arthroscopy with a change in pump pressure of 15 mmHg set as the marker of surgeon visualization of the shoulder joint during surgery.

  2. Postoperative pain [ Time Frame: 7 days ]
    Investigators will be measuring whether there is a decrease in participants pain after surgery as assessed by visual analog score 7 days after surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • participants aged 18-80
  • participants with an ASA (American Society of Anesthesiologists) score 1-3
  • participants with a surgical indication of full thickness small to massive rotator cuff tear.

Exclusion Criteria:

  • pregnant females,
  • participants with a known allergy to tranexamic acid,
  • participants with active thromboembolic disease,
  • participants with seizure disorder,
  • participants with prior cerebrovascular accident (CVA),
  • history of cardiac stents or past history of thromboembolic disease,
  • presence of full-thickness subscapularis tear (>50%),
  • participants with irreparable rotator cuff tears.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04610164

Layout table for location information
United States, Pennsylvania
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Rothman Institute Orthopaedics
Layout table for additonal information
Responsible Party: Rothman Institute Orthopaedics Identifier: NCT04610164    
Other Study ID Numbers: SNAM18d.610
First Posted: October 30, 2020    Key Record Dates
Last Update Posted: October 30, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action